Although the majority of these studies have focussed on ALDH1A1, ALDH3A1 has been reported to be upregulated in prostate cancer stem cells and in metastatic lesions compared with primary tumours [22] as well as being required for stem cell maintenance and resistance to cytotoxic drugs [23, 24]. Here, ALDH3A1 is linked to prostate carcinoma.